-
1
-
2
Upadacitinib in active non-radiographic axial spondyloarthritis: 2-year data from the phase 3 SELECT-AXIS 2 study
Published 2025-02-01“…Abstract Background In SELECT-AXIS 2, upadacitinib improved the signs and symptoms of active non-radiographic axial spondyloarthritis (nr-axSpA) through 52 weeks versus placebo and was well tolerated. …”
Get full text
Article -
3
Evaluation of 1.5mm Lead Shield for Radiological Protection and Comparison of Calculated and Measured Results of Equivalent Dose
Published 2020-01-01Subjects: Get full text
Article -
4
Evaluation of 1.5mm Lead Shield for Radiological Protection and Comparison of Calculated and Measured Results of Equivalent Dose
Published 2020-01-01Subjects: Get full text
Article -
5
Robotic Assistance in Simultaneous Bilateral Medial Unicompartmental Knee Arthroplasty: A Retrospective Cohort Study of 126 Knees Demonstrating Enhanced Radiographic Accuracy and Comparable Safety to Conventional Methods
Published 2025-02-01“…This study aims to compare the safety, early clinical and functional outcomes, and radiological results of conventional vs robotic-assisted medial BUKA. …”
Get full text
Article -
6
Long-term safety and sustained efficacy of bimekizumab in patients with ankylosing spondylitis (radiographic axial spondyloarthritis): 5-year results from BE AGILE (phase 2b) and its open-label extension
Published 2025-01-01“…Objective Assess long-term safety, tolerability and efficacy of bimekizumab in ankylosing spondylitis (radiographic axial spondyloarthritis (r-axSpA)).Methods Patients with active r-axSpA completing the dose-ranging 48-week randomised controlled trial could enrol in the open-label extension, where patients received bimekizumab 160 mg every 4 weeks. …”
Get full text
Article -
7
Safety of brigatinib following alectinib-induced-pneumonitis: Case report
Published 2025-01-01Get full text
Article -
8
Development of the modified Safety Attitude Questionnaire for the medical imaging department
Published 2025-01-01“…These errors are frequently influenced by patient safety culture. This study aimed to develop a suitable patient safety culture assessment tool for medical imaging departments. …”
Get full text
Article -
9
Toxicity and Safety Evaluation of Doxorubicin-Loaded Cockleshell-Derived Calcium Carbonate Nanoparticle in Dogs
Published 2018-01-01“…The study confirmed the safety of repeated dose administration of CS-CaCO3NP-DOX (30 mg/m2) for 5 cycles in dogs. …”
Get full text
Article -
10
Complications during chest tube drainage for iatrogenic pneumothorax
Published 2025-12-01“…However, guidance on iatrogenic pneumothorax occurring in patients with impaired lung function, increased age, comorbidity and frailty is lacking, and the safety profile of ambulatory management is not known. …”
Get full text
Article -
11
-
12
Efficacy and safety of long fusion versus short fusion in degenerative scoliosis: a systematic review and meta-analysis
Published 2025-01-01“…Abstract Background This study aimed to evaluate the efficacy and safety of long fusion versus short fusion in patients with degenerative scoliosis. …”
Get full text
Article -
13
Safety and Efficiency of Biomimetic Nanohydroxyapatite/Polyamide 66 Composite in Rabbits and Primary Use in Anterior Cervical Discectomy and Fusion
Published 2014-01-01“…This study was conducted to validate the safety and efficiency of biomimetic nanohydroxyapatite/polyamide 66 (n-HA/PA66) composite in animal model (rabbit) and report its application in anterior cervical discectomy and fusion (ACDF) for 4, 12, and 24 weeks. …”
Get full text
Article -
14
The Effectiveness and Safety of Tibial-Sided Osteotomy for Fibula Untethering in Lateral Close-Wedge High Tibial Osteotomy: A Novel Technique with Video Illustration
Published 2025-01-01“…The purposes of this study were to introduce the TSO technique and compare the complexity and safety of TSO with those of radiographic virtual PTFJD, which is defined based on radiographic landmarks representing the traditional PTFJD technique. …”
Get full text
Article -
15
Safety of Occlutech Septal Occluder ACCELL Flex II for Transcatheter Closure of Secundum Atrial Septal Defects in Children: A Long-Term Follow-Up
Published 2022-01-01“…To assess the long-term safety and efficacy of the Occlutech® ACCELL® Flex II device used for atrial septal defect (ASD) closure. …”
Get full text
Article -
16
Efficacy and safety of jaktinib hydrochloride tablets in active axial spondyloarthritis: a multicentre, randomised, double-blind, placebo-controlled phase II clinical trial
Published 2025-01-01“…Objective The objective of this study is to evaluate the efficacy and safety of jaktinib hydrochloride tablets (jaktinib), a Janus kinase inhibitor, in patients with active radiographic axial spondyloarthritis (r-axSpA).Methods Adults with active r-axSpA who met modified New York criteria and had an inadequate response to non-steroidal anti-inflammatory drugs were randomised 1:1:1 to receive jaktinib 75 mg two times per day, 100 mg two times per day, or placebo. …”
Get full text
Article -
17
Effectiveness and Safety of Preoperative Halo Gravity Traction-Assisted Posterior Spinal Fusion Surgery for Severe and Rigid Scoliosis: A Comparative Matched-Cohort Study
Published 2024-01-01“…Comprehensive assessments including radiographic outcomes, surgical parameters, and clinical complications were collect and analyzed before and after correction surgery. …”
Get full text
Article -
18
Secukinumab in the treatment of psoriatic arthritis: efficacy and safety results through 3 years from the year 1 extension of the randomised phase III FUTURE 1 trial
Published 2018-08-01“…Exposure-adjusted incidence rates for selected adverse events per 100 patient-years (secukinumab 150/75 mg) were serious infections (1.7/1.6), Candida infections (1.4/0.7), Crohn’s disease (0/0.3), ulcerative colitis (0/0.3) and major adverse cardiac events (0.3/0.8).Conclusion Subcutaneous secukinumab provided sustained improvements in the signs and symptoms, quality of life and physical function of patients with active PsA with low rate of radiographic disease progression through 3 years. Secukinumab was well tolerated with no new safety signals.…”
Get full text
Article -
19
Efficacy and safety of perioperative sintilimab plus platinum-based chemotherapy for potentially resectable stage IIIB non-small cell lung cancer (periSCOPE): an open-label, single...
Published 2025-01-01“…Nineteen patients achieved a radiographic partial response, resulting in an ORR of 63.3%. …”
Get full text
Article -
20
Safety and tumour-specific immunological responses of combined dendritic cell vaccination and anti-CD40 agonistic antibody treatment for patients with metastatic pancreatic cancer:...
Published 2022-06-01“…The primary endpoint is safety and tolerability of the combination immunotherapy. …”
Get full text
Article